BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 2446081)

  • 1. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML; Schenck KW; Kurz KD
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ; Reneman RS
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal hemodynamic effects of ketanserin therapy in essential hypertension.
    Ram CV; Gonzalez DG; Kaplan NM; Ralakis JM; Henderson JD; Lugo CE; Zachariah N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S78-80. PubMed ID: 2446078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of acute and chronic effects of ketanserin in the treatment of hypertension and hypothesis on a new mechanism of action].
    Sechi LA
    Ann Ital Med Int; 1990; 5(4 Pt 2):433-50. PubMed ID: 2102130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of ketanserin on arterial pressure at rest and during physical exercise in essential arterial hypertension].
    Gambini G; Gradoli C; Proietti MG; Pinchi G; Fioroni E; Valori C
    Clin Ter; 1989 Jul; 130(2):101-7. PubMed ID: 2529082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
    de Lorenzo A; Ceccanti M; Assogna G; Romeo M; Cavaleri G; Attilia ML
    Int J Clin Pharmacol Res; 1988; 8(5):321-5. PubMed ID: 3068159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
    Nelson M; Coghlan JP; Denton DA; Tresham JJ; Whitworth JA; Scoggins BA
    Clin Exp Pharmacol Physiol; 1987 Jul; 14(7):555-63. PubMed ID: 3124998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.
    Smits J; van Dorsten F; Struyker Boudier H
    Drugs; 1988; 36 Suppl 1():55-60. PubMed ID: 3149239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
    Balasubramaniam G; Lee HS; Mah SC
    J Pharmacol Exp Ther; 1993 Jan; 264(1):129-34. PubMed ID: 8093720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of pharmacologic blockade of serotonin receptors (S2) on arterial pressure in rats with 2 forms of hereditary arterial hypertension].
    Popova NK; Piianzin AI; Markel' AL
    Farmakol Toksikol; 1989; 52(6):58-61. PubMed ID: 2516487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
    Ikeda K; Takata M; Tomoda F; Mikawa M; Iida H; Sasayama S
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S69-72. PubMed ID: 2446076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
    Hedner T; Pettersson A; Persson B
    J Hypertens Suppl; 1986 Apr; 4(1):S91-3. PubMed ID: 2939221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of the serotonergic antagonist ketanserin.
    Stott DJ; Robertson JI; Ball SG
    J Hypertens Suppl; 1985 Dec; 3(3):S191-3. PubMed ID: 2856702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hemodynamic and humoral effects of 2 different doses of ketanserin in aged patients with hypertension].
    Rizzoni D; Castellano M; Beschi M; Agabiti-Rosei E
    Ann Ital Med Int; 1990; 5(4 Pt 2):489-96. PubMed ID: 2102136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats.
    Docherty JR
    J Pharmacol Exp Ther; 1989 Feb; 248(2):736-40. PubMed ID: 2537414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.